We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Teladoc (TDOC) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
The upcoming report from Teladoc (TDOC - Free Report) is expected to reveal quarterly loss of -$0.24 per share, indicating a decline of 26.3% compared to the year-ago period. Analysts forecast revenues of $614.69 million, representing a decline of 2.7% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Teladoc metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenues by Segment- BetterHelp' will likely reach $221.80 million. The estimate suggests a change of -7.7% year over year.
The consensus among analysts is that 'Revenues by Segment- Integrated Care' will reach $392.17 million. The estimate suggests a change of +0.2% year over year.
Analysts expect 'U.S. Integrated Care Members' to come in at 99.61 million. The estimate compares to the year-ago value of 102.40 million.
The average prediction of analysts places 'Adjusted EBITDA- BetterHelp' at $1.77 million. The estimate is in contrast to the year-ago figure of $11.86 million.
Based on the collective assessment of analysts, 'Adjusted EBITDA- Integrated Care' should arrive at $59.25 million. Compared to the present estimate, the company reported $57.45 million in the same quarter last year.
Teladoc shares have witnessed a change of +2.5% in the past month, in contrast to the Zacks S&P 500 composite's +1.7% move. With a Zacks Rank #3 (Hold), TDOC is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Seeking Clues to Teladoc (TDOC) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
The upcoming report from Teladoc (TDOC - Free Report) is expected to reveal quarterly loss of -$0.24 per share, indicating a decline of 26.3% compared to the year-ago period. Analysts forecast revenues of $614.69 million, representing a decline of 2.7% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Teladoc metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenues by Segment- BetterHelp' will likely reach $221.80 million. The estimate suggests a change of -7.7% year over year.
The consensus among analysts is that 'Revenues by Segment- Integrated Care' will reach $392.17 million. The estimate suggests a change of +0.2% year over year.
Analysts expect 'U.S. Integrated Care Members' to come in at 99.61 million. The estimate compares to the year-ago value of 102.40 million.
The average prediction of analysts places 'Adjusted EBITDA- BetterHelp' at $1.77 million. The estimate is in contrast to the year-ago figure of $11.86 million.
Based on the collective assessment of analysts, 'Adjusted EBITDA- Integrated Care' should arrive at $59.25 million. Compared to the present estimate, the company reported $57.45 million in the same quarter last year.
View all Key Company Metrics for Teladoc here>>>Teladoc shares have witnessed a change of +2.5% in the past month, in contrast to the Zacks S&P 500 composite's +1.7% move. With a Zacks Rank #3 (Hold), TDOC is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .